Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) shares were down 3.7% on Tuesday . The stock traded as low as $4.43 and last traded at $4.43. Approximately 800 shares changed hands during trading, a decline of 100% from the average daily volume of 237,210 shares. The stock had previously closed at $4.60.
Innovent Biologics Stock Performance
The firm’s 50-day moving average is $4.94 and its two-hundred day moving average is $5.15.
About Innovent Biologics
Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.
Featured Articles
- Five stocks we like better than Innovent Biologics
- How to Evaluate a Stock Before BuyingÂ
- Comprehensive PepsiCo Stock Analysis
- Dividend Payout Ratio Calculator
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- What is Forex and How Does it Work?
- Bear Market Funds to Watch This Year
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
